Moreover, pharmacological tools to specifically affect the OADH function may be of therapeutic significance, as regulation of the DHTKD1 expression is observed in a number of pathological conditions, including diabetes, obesity and malignant transformation. The gene discussed is DHTKD1; the disease is obesity due to melanocortin 4 receptor deficiency.